Congressman Ami Bera | Official U.S. House headshot
Congressman Ami Bera | Official U.S. House headshot
WASHINGTON, DC – On June 8, Representatives Ami Bera, M.D. (D-CA), Brian Fitzpatrick (R-PA), Derek Kilmer (D-WA), and Mike Kelly (R-PA) led 66 Members of Congress in a bipartisan letter to the U.S. Department of Health and Human Services Secretary Xavier Becerra and U.S. Food and Drug Administration Commissioner Robert Califf expressing concern with the detrimental impact of drug shortages on individuals battling cancer.
Out of the 136 drugs currently in shortage, as reported by the FDA, 15 of them are oncology medications that are widely used in the treatment of common cancers, including lung, breast, ovarian, testicular, head and neck cancer, endometrial cancer, and many types of cancers impacting children.
In the letter, the lawmakers wrote:
“Patients, physicians, and pharmacists are often the last to know when an essential drug will no longer be available, yet, are affected by these shortages the most. We strive to ensure patients, physicians, and pharmacists never have to experience shortages of essential medications, but when shortages do occur it is vital that these individuals are made aware as quickly as possible so that they can better prepare.
We appreciate the actions FDA has already taken to address the ongoing cancer drug shortage and encourage you to take all appropriate steps to protect this vulnerable population. We stand ready to assist you in any way possible.”
The consequences of these drug shortages are particularly dire, affecting both adult and pediatric patients. Many community cancer centers are now unable to provide necessary treatments due to the scarcity of cancer drugs and large academic cancer centers have reported having less than a two-week supply of these vital medications on hand.
Click here for the full letter.
Original source can be found here
Alerts Sign-up